InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| General and administrative expenses | $1.8M+154.0% | $703K+13959.2% | $5K |
| Loss from operations | -$1.8M-154.0% | -$703K-13959.2% | -$5K |
| Interest income | $11K+19.7% | $10K+0.0% | $10K |
| Income from investments held in Trust Account | $10.8M+130.2% | $4.7M+0.0% | $4.7M |
| Unrealized gain on investments held in Trust Account | $159K | — | $159K |
| Total other income | $10.8M+122.4% | $4.8M | — |
| Net income | $9.0M+117.1% | $4.1M+82927.4% | -$5K |
| Weighted average shares outstanding of Class A redeemable ordinary shares, basic and diluted | $25.3M+157.7% | $9.8M | — |
| Basic and diluted net income per ordinary share, Class A Redeemable ordinary shares | $0.28+7.7% | $0.26 | — |
| Weighted average shares outstanding of Class B ordinary shares, basic | $6.3M+8.7% | $5.8M-40.7% | $9.8M |
| Basic net income per ordinary share, Class B ordinary shares | $0.28+7.7% | $0.26 | — |
| Weighted average shares outstanding of Class B ordinary shares, diluted | $6.3M+0.0% | $6.3M-35.6% | $9.8M |
| Diluted net income per ordinary share, Class B ordinary shares | $0.28+16.7% | $0.24 | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
Voyager Acquisition receives approval for combination with Veraxa Biotech
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG